Pharmarise Holdings Corporation

Equities

2796

JP3802320006

Drug Retailers

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
639 JPY -2.59% Intraday chart for Pharmarise Holdings Corporation -1.54% -3.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pharmarise Holdings’ Attributable Profit Down 15% in Fiscal Nine Months on Higher Expenses Following M&A MT
Pharmarise Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024 CI
Tranche Update on Pharmarise Holdings Corporation's Equity Buyback Plan announced on January 11, 2024. CI
Pharmarise Holdings Corporation announces an Equity Buyback for 1,416,800 shares, representing 12.07% for ¥1,032 million. CI
Pharmarise's Fiscal H1 Attributable Profit Soars as Net Sales Rise MT
Pharmarise Holdings Corporation authorizes a Buyback Plan. CI
Pharmarise Holdings Corporation entered into stock transfer agreement to acquire GOOD AID Inc. from Kotoshino Co., Ltd. and Yuta Hattori. CI
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024 CI
Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 CI
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2024 CI
Pharmarise Holdings Corporation acquired Nine Dispensing Pharmacies in Tokyo, Niigata, and Fukushima. CI
Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 CI
Pharmarise Holdings Corporation Announces Commemorative Dividend for the Fiscal Year Ending May 31, 2024 CI
Pharmarise Holdings Corporation Declares Dividend for the Fiscal Year Ending May 31, 2023, Payable on August 31, 2023 CI
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2024 CI
Pharmarise Logs 35% Drop in FY23 Nine-month Profit on Higher Utility Expenses, Lower Drugstore Sales MT
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2023 CI
Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2023 CI
Pharmarise Holdings Corporation entered into basic agreement to acquire Two Dispensing Pharmacies in Mie Prefecture. CI
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2023 CI
Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2023 CI
Pharmarise's Fiscal Q1 Attributable Profit Soars 75% MT
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2023 CI
Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2023 CI
Pharmarise Logs 5% Jump in FY22 Attributable Profit, Maintains Final Dividend MT
Chart Pharmarise Holdings Corporation
More charts
Pharmarise Holdings Corporation is a Japan-based holding company primarily engaged in the dispensing pharmacy businesses. Along with its subsidiaries and associated companies, the Company operates in five business segments. The Dispensing Pharmacy segment is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on prescriptions issued by medical institutions. The Merchandising segment consists of the cosmetics sales business, the convenience store management business and the drug store management business. The Medical Document Storage and Management segment is engaged in the storage and management of paper medical records and X-ray films. The Medical Mall Management segment is a business related to medical malls operated at JR Tower Office Plaza Sapporo in JR Sapporo Station. Others segment includes temporary staffing business and sales of stationery.
More about the company
  1. Stock Market
  2. Equities
  3. 2796 Stock
  4. News Pharmarise Holdings Corporation
  5. Pharmarise's Fiscal H1 Attributable Profit Soars as Net Sales Rise